Increasing anthracyclines efficacy in Triple Negative Breast Cancer cells by disrupting cells defense mechanism and evaluating Caspase-3 as indicator for anthracyclines hematologic toxicity in breast cancer patients
Chemotherapy is the backbone of systemic treatment for triple negative breast cancer (TNBC), among which anthracyclines are important agents and represent the current standard treatment option. However, treatment failure usually happens due to the drug resistance developed by TNBC cells. Especially...
Saved in:
Main Author: | Luo, Man |
---|---|
Other Authors: | Lim Sierin |
Format: | Thesis-Doctor of Philosophy |
Language: | English |
Published: |
Nanyang Technological University
2020
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/136588 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes
by: Chan, D., et al.
Published: (2014) -
Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy
by: Chan, A., et al.
Published: (2014) -
Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer
by: Aminkeng, Folefac, et al.
Published: (2022) -
Extracellular Vesicle Proteome of Breast Cancer Patients with and Without Cognitive Impairment Following Anthracycline-based Chemotherapy: An Exploratory Study
by: Koh, YQ, et al.
Published: (2022) -
Triple-negative Breast Cancer
by: Panuwat Lertsithichai
Published: (2022)